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Chikungunya virus (CHIKV) is associated with outbreaks of
infectious rheumatic disease in humans. Using a mouse
model of CHIKV arthritis and myositis, we show that tumor
necrosis factor–a, interferon-c, and monocyte chemotactic
protein 1 (MCP-1) were dramatically induced in tissues from
infected mice. The same factors were detected in the serum of
patients with CHIKV-induced polyarthralgia and polyarthritis,
with MCP-1 levels being particularly elevated. Bindarit (MCP
inhibitor) treatment ameliorated CHIKV disease in mice.
Histological analysis of muscle and joint tissues showed a re-
duction in inflammatory infiltrate in infected mice treated with
bindarit. These results suggest that bindarit may be useful in
treating CHIKV-induced arthritides in humans.
Alphaviruses can cause significant inflammatory pathologies,
ranging from arthritis to encephalitis. Emerging alphaviruses
such as Chikungunya virus (CHIKV), Mayaro virus, and
O’nyong-nyong virus are considered significant public health
threats by the World Health Organization, with severe cases of
debilitating arthritis and arthralgia being reported from a wide
range of geographic locations [1].
CHIKV is a positive-sense alphavirus endemic to Africa,
India, and Southeast Asia [2]. Infection with CHIKV typically
leads to a human disease syndrome involving myalgia, arthritis,
arthralgia, rash, and severe lethargy [3]. In a substantial number
of patients, symptoms can persist or recur for months or even
years following initial infection [4]. In recent CHIKV epidemics,
there were a small number of deaths involving neonates and the
elderly, or adults with underlying medical conditions [5].
In recent years there have been a number of major outbreaks
of CHIKV infection. For example, approximately 250 000 people
in Re´union were infected with CHIKV during an epidemic in
2005–2006, and subsequently an additional 3 million individuals
were infected during an epidemic in India [2].
The mechanisms by which arthritogenic alphaviruses such as
CHIKV cause disease are poorly understood. In a macaque
model, Labadie et al first identified macrophages as the main
cellular reservoirs for CHIKV infection [6]. Recently, the pres-
ence of CHIKV antigen and RNA was shown in synovial mac-
rophages of CHIKV patients [7]. In a chronic case of CHIKV
infection, macrophage infiltration of synovium was detected,
suggesting that these cells may play an important role in joint
inflammation following CHIKV infection [7]. A mouse model of
CHIKV disease was recently established by Gardner et al, who
proposed that macrophages were essential in CHIKV-induced
muscle and ankle joint inflammation [8]. Recent mouse studies
provided some evidence for muscle and joint inflammation and
associated damage as being the likely cause of CHIKV-induced
symptoms in mice [8]. The foot and skeletal muscle were sites of
high-level viral replication with tissue inflammatory infiltrates
comprising monocytes, macrophages, natural killer cells, and
CD4 and CD8 T cells [8]. Studies in the mouse and macaque
models have characterized joint and muscle pathology and the
relevance of these models to human disease [6, 8]. Similar mouse
studies with the related alphavirus Ross River Virus (RRV) have
shown that this virus particularly targets the muscle, bone, and
joint, leading to macrophage-driven inflammation of these tis-
sues [9]. The importance of macrophages in the mouse model of
RRV arthritis was demonstrated by Lidbury et al, who showed
that depletion of macrophages using the macrophage-specific
inhibitor clodronate significantly reduced joint and muscle in-
flammation [10].
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Current treatment for CHIKV infection is symptomatic, in-
volving analgesics and nonsteroidal anti-inflammatory drugs
(NSAIDs), which provide partial relief from rheumatic symp-
toms [1]. There is an urgent need for the development of im-
proved therapies for infection with CHIKV, particularly because
no licensed vaccine is available.
In this study, we tested the efficacy of a small molecule anti-
inflammatory drug, bindarit, in the mouse model of CHIKV
disease. Bindarit functions largely by inhibiting production of
monocyte chemotactic proteins (MCPs) [11], which are key
regulators of macrophage migration into sites of inflammation.
Mice treated with bindarit were protected from inflammation of
joint and skeletal muscle tissues following CHIKV infection.
This is the first study to report the critical role of MCP-1 in
CHIKV-induced arthritis and myositis and highlights the ther-
apeutic potential of MCP inhibitors in CHIKV disease.
MATERIALS AND METHODS
Patient Serum Samples
Paired acute serum samples from patients presenting with febrile
illness, polyarthralgia, and polyarthritis suspected of having
CHIKV infection were tested by CHIKV serology at the Ministry
of Public Health (MOPH), Thailand. CHIKV infection was
defined as a 4-fold rise in hemagglutination inhibition antibody
titers in acute and convalescent sera. Twenty-five serum samples
from patients with positive CHIKV serology were selected for
measurement of cytokines by enzyme-linked immunosorbent
assay (ELISA; R&D Systems). Serum from 10 healthy individuals
with negative CHIKV serology was also analyzed. Studies were
approved by MOPH Thailand.
Mouse Infection
Twenty-four-day-old C57BL/6 mice were inoculated sub-
cutaneously with 104 plaque-forming units (PFU) of CHIKV
(Re´union isolate passaged twice in C6/36 cells) or RRV. Control
animals were injected with diluent only. Mice were scored for
disease symptoms every day for 20 days. Mice were sacrificed by
CO2 asphyxiation, and the serum, quadriceps muscles, and ankle
joints were removed for cytokine measurement by ELISA (R&D
Systems) and determination of virus titers as described pre-
viously [8, 9]. Quadriceps muscles and ankle joints were also
collected for histological analysis as described previously [10].
Mice were held and manipulated in accordance with in-
stitutional guidelines that are in compliance with the National
Institutes of Health (NIH) Guide for the Care and Use of Lab-
oratory Animals (NIH publication number 85-23, 1985). The
experimental protocols were approved by the University of
Canberra and Angelini Research Center research committees.
Bindarit Treatment of Mice
Bindarit, 2-methyl-2-[[1-(phenylmethyl)-1H-indazol-3-yl] me-
thoxy] propanoic acid (Angelini Research Center, Rome, Italy)
was given intraperitoneally tomice (100mg/kg) or vehicle (0.5%
methylcellulose, Sigma) twice a day from day of infection for
5 days.
Statistical Analysis
Mouse cytokine analyses were carried out using the Student
unpaired t test. Data for mouse disease scores and human cyto-
kines were analyzed using Mann–Whitney U test. Data were
considered statistically significant at P , .05.
RESULTS
High Levels of Proinflammatory Cytokines Are Detected in
CHIKV-Infected Humans and Mice
Levels of proinflammatory cytokines were measured in serum
from patients suffering from acute CHIKV-induced poly-
arthralgia and polyarthritis. Samples from CHIKV-infected
individuals were collected during the acute phase of the
disease, on average 4 (SD 5.8) days after the onset of the dis-
ease. Serum from patients with acute CHIKV-induced poly-
arthralgia and polyarthritis had significantly higher levels of
MCP-1 (P5 .0015; Figure 1A), tumor necrosis factor (TNF)–a
(P 5 .0285; Figure 1B), and interferon (IFN)–c (P 5 .0263;
Figure 1C) compared with serum from healthy individuals. The
average platelet count was 236 588 cells/ll, ranging from
115 000 to 316 000 cells/ll. There were no correlations between
platelet counts and the levels of MCP-1, IFN-c, or TNF-a. In
addition, MCP-1, TNF-a, and IFN-c were measured in serum
and homogenized skeletal muscle and ankle joint tissues of
alphavirus-infected mice. The amount of MCP-1, TNF-a, and
IFN-c proteins produced by infected mice was greater than that
in uninfected control mice (Figure 1D–F). These findings are
consistent with the prominent increase in MCP-1 and IFN-c
and, to a lesser extent, TNF-a that was reported in a primate
model of CHIKV infection [6].
Bindarit Treatment Ameliorated CHIKV-Induced Disease
Since MCP-1 levels were detected at high levels in patients and
mice with CHIKV disease, we tested the therapeutic potential of
bindarit, an inhibitor of MCP-1 synthesis, in CHIKV disease in
mice. Bindarit-treated or untreated mice were infected with 104
PFU of CHIKV and animals were monitored for the development
of disease signs. Infection of untreated mice resulted in severe
disease with peak clinical scores observed on day 10 after in-
fection (Figure 2A). In contrast, disease signs in bindarit-treated
mice were mild and of much shorter duration (Figure 2A).
We tested whether differences in viral titers in the ankle
joint or skeletal muscle could explain the reduced severity of
disease observed following bindarit treatment of CHIKV-
infectedmice. Analysis showed no significant differences in virus
titers in bindarit-treated CHIKV-infected mice compared with
untreated infected mice at all time points after infection (not
shown).
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To determine the effects of bindarit treatment on tissue in-
flammation and pathology, hind limb joint and skeletal muscle
tissues were observed by histology. Inflammation was abolished
in synovial tissue and skeletal muscle in bindarit-treated mice
infected with CHIKV (Figure 2B, ii, iv, vi). In contrast, severe
inflammation was observed in synovial tissue and skeletal muscle
of the infected control group at 10 days after infection. (Figure 2B,
i, iii, v). Extensive disruption of striated muscle fibers was evident
in infected untreated mice, while muscle tissue from infected
bindarit-treated mice exhibited no detectable damage.
DISCUSSION
In this paper we demonstrated that (1) high levels of proin-
flammatory cytokines, namely MCP-1 and TNF-a, are produced
following CHIKV infection in humans and mice and (2) the
MCP-1 synthesis inhibitor bindarit can ameliorate disease
symptoms and tissue damage associated with CHIKV infection in
mice. These results highlight the potential for anti-inflammatory
strategies that target macrophage migration for the treatment of
CHIKV disease.
The recently established mouse model of CHIKV disease re-
capitulates many aspects of the human disease and serves as an
accurate model to study disease pathogenesis and new treatment
options. At present, alphavirus-induced arthritic diseases are
mainly treated with NSAIDs, which provide some symptomatic
relief but do not significantly modify the underlying disease
processes. Bindarit treatment markedly reduced disease symp-
toms and tissue damage associated with CHIKV infection.
A recent study suggested that inflammatory cells cause the
musculoskeletal symptoms and tissue damage in CHIKV-
infected mice [8], and our results support this conclusion by
showing a correlation between the therapeutic effects of bindarit
and its ability to reduce the influx of inflammatory cells into
muscle and joint tissue. Bindarit treatment led to reduced ex-
pression of MCP-1 and TNF-a in muscle and joint tissues in
CHIKV-infected mice (not shown), consistent with the recently
described ability of bindarit to inhibit production of these cy-
tokines in RRV-infected mice [12]. The reduction in MCP-1
production contributed to the decreased macrophage in-
filtration into tissues (not shown), while lower levels of TNF-a,
one of the several proinflammatory products of macrophages,
are also likely to contribute to the reduced tissue destruction
observed in bindarit-treated mice. Furthermore, bindarit treat-
ment commencing on day 5 after infection (established disease)
can prevent the development of severe disease, suggesting that
the administration of bindarit at the onset of symptoms can
have a therapeutic effect (not shown).
The inhibition of cytokines with antibodies or small mol-
ecule inhibitors promises benefits in a range of inflammatory
Figure 1. Proinflammatory cytokines are upregulated in the serum of patients with acute Chikungunya (CHIK) infection and in the tissues of alphavirus-
infected mice. (A–C ) Acute serum samples from patients presenting with febrile illness and polyarthritis (25 positive for CHIK) and 10 healthy controls were
depersonalized and the levels of monocyte chemotactic protein (MCP)–1, tumor necrosis factor (TNF)–a, and interferon (IFN)–c were measured by enzyme-
linked immunosorbent assay (ELISA). Each point represents a single patient sample. Significant differences are marked by an asterisk. (D–F) C57BL/6 mice
were infected subcutaneously with 104 plaque-forming units of CHIK or Ross River Virus or mock-infected with diluent alone. At day 10 after infection, mice
were sacrificed and serum, ankle joint, and quadriceps muscle tissues were collected. Ankle joint and quadriceps muscle tissues were homogenized in
phosphate-buffered saline. Cell debris was pelleted following centrifugation and the supernatant was collected and stored at280°C. Protein levels of MCP-1,
TNF-a, and IFN-c in tissues of virus-infected mice (n 5 4) and mock-infected mice (n 5 4) were determined by ELISA (performed in duplicate).
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Figure 2. Bindarit treatment ameliorates Chikungunya (CHIKV) disease in mice. Mice were infected subcutaneously with 104 plaque-forming units of
CHIKV. Mock-infected mice were injected with phosphate-buffered saline alone. Mice received peritoneal injections of bindarit or the corresponding
vehicle twice a day from day of infection for 5 days. A, Disease signs were determined by assessing grip strength and altered gait based on the following
scales: 0, no disease; 1, ruffled fur; 2, very mild hind limb weakness; 3, mild hind limb weakness; 4, moderate hind limb weakness; 5, severe hind limb
weakness/dragging; 6, complete loss of hind limb function; 7, moribund; 8, death. Each data point represents the mean 6 SD for 7 mice per group.
Significant differences are marked by an asterisk. B, At 10 days after infection, mice were perfused with 4% paraformaldehyde and 5-lm-thick paraffin-
embedded sections from quadriceps muscle were stained with hematoxylin and eosin (H&E); (i) CHIKV-infected, vehicle-treated mice, (ii) CHIKV-infected,
bindarit-treated mice. Following decalcification, 5-lm-thick, paraffin-embedded sections generated from ankle joints were stained with H&E; (iii and v)
CHIKV-infected, vehicle-treated mice and (iv and vi) CHIKV-infected, bindarit-treated mice. B, bone; M, muscle; P, periosteum; ST, synovial tissue. The
images are representative of 4 mice per group. Magnification: i, ii (4003); iii, iv (1003); v, vi (2003).
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diseases [13]. The most successful therapeutic cytokine in-
hibitors are biologics developed to inhibit the function of
TNF-a, which have been very successful in treating numerous
inflammatory diseases, particularly rheumatoid arthritis.
However, concerns have been raised about the safety profile of
these drugs, with a minority of patients suffering from severe
infections, presumably due to an impaired inflammatory re-
sponse [14]. Indeed, we found that treatment of RRV-infected
mice with the TNF inhibitor etanercept resulted in a marked
exacerbation of arthritis and myositis and increased viral load
[15]. The efficacy and low toxicity of bindarit in several ani-
mal models of inflammatory disease demonstrate that small
molecule inhibitors of the cytokine/chemokine system should
be seriously considered as potential therapeutics for arthritis
resulting from infection with CHIKV.
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